Gilead Sciences GILD Vemlidy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's vemlidy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's vemlidy — total revenues?
- Gilead Sciences (GILD) reported vemlidy — total revenues of $237M in Q1 2026.
- How has Gilead Sciences's vemlidy — total revenues changed year-over-year?
- Gilead Sciences's vemlidy — total revenues decreased by 6.0% year-over-year, from $252M to $237M.
- What is the long-term trend for Gilead Sciences's vemlidy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's vemlidy — total revenues has grown at a 7.1% compound annual growth rate (CAGR), from $814M to $1.07B.
- What does vemlidy — total revenues mean?
- The total sales revenue generated by the specific liver disease medication Vemlidy.
- How do you interpret vemlidy — total revenues?
- An increase in revenue indicates strong market penetration, successful patient retention, or expanded clinical adoption of the therapy. A decrease may signal increased competition from generics, loss of patent exclusivity, or shifts in clinical treatment guidelines.
- How does vemlidy — total revenues compare across companies?
- Comparable to product-specific revenue lines reported by other biopharmaceutical companies, such as branded drug sales in oncology or immunology segments.